Promising Five-Year Results for LUMEVOQ® Gene Therapy in LHON Patients
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of sustained therapeutic benefits offers significant hope. GenSight Biologics recently announced the publication of five-year outcomes for patients treated unilaterally with their gene therapy, LUMEVOQ® (lenadogene nolparvovec), for Leber Hereditary Optic Neuropathy (LHON) caused by the MT-ND4 gene variant. These long-term results, published in JAMA Ophthalmology in December 2024, indicate a sustained improvement in visual acuity and a favorable safety profile, providing crucial insights into the durability of this treatment for a rare and often devastating condition.
LHON is a rare, maternally inherited mitochondrial genetic disorder that typically leads to rapid, painless vision loss, often progressing to severe visual impairment and legal blindness, primarily affecting young adults. The MT-ND4 gene variant is one of the most common causes of LHON. LUMEVOQ® is designed to address the root cause of LHON in patients with this specific mutation by delivering a functional copy of the ND4 gene to retinal ganglion cells, aiming to restore mitochondrial function and protect vision.
The recently published data comes from the RESTORE study, a long-term follow-up study that included participants from the earlier Phase III RESCUE and REVERSE trials. These participants had received a single intravitreal injection of LUMEVOQ® in one eye and a sham injection in the other. The findings demonstrate that five years after the one-time injection, patients experienced a sustained bilateral improvement in Best-Corrected Visual Acuity (BCVA). Specifically, LUMEVOQ®-treated eyes showed a mean improvement of +22 letters equivalent against nadir (the lowest point of visual acuity), while sham-treated eyes also demonstrated a mean improvement of +20 letters equivalent.
Beyond visual acuity, the study also reported increases in self-reported quality of life scores at Year 5 compared to baseline, with a clinically meaningful gain of 7 points in the composite score. Safety findings over the five-year period were consistent with previous observations, confirming that LUMEVOQ® was well-tolerated. Most ocular events were mild, and no severe or serious adverse events led to study discontinuation. At the five-year mark, 80.6% of participants maintained on-chart vision (BCVA ≤ 1.6 LogMAR) in at least one eye.
These results are particularly meaningful for patients and their families, as they highlight the potential for long-term visual benefits and an improved quality of life following a single gene therapy treatment. The sustained improvement observed in both treated and sham-treated eyes is a significant aspect of the findings, suggesting a potential indirect effect or natural history of the disease in the context of the study. The RESTORE study, with 62 participants, represents one of the largest long-term follow-up studies for a rare disease treatment.
GenSight Biologics continues to advance its gene therapy programs, and these long-term outcomes provide valuable evidence of the sustained efficacy and safety profile of LUMEVOQ® for ND4 LHON. The ongoing research and follow-up will continue to build our understanding of the long-term impact of gene therapy on inherited retinal diseases.